Demand for antibody-drug conjugates (ADCs) took a leap on 9 January after Netherlands-based Synaffix BV disclosed two new deals for its proprietary ADC technology. The first agreement is with Mitsubishi Tanabe Pharma Corp of Japan and the second with Boehringer Ingelheim GmbH of Germany. The value of the Mitsubishi deal was not disclosed, however that with Boehringer involves a potential milestone payment of up to $1.3 billion in addition to an undisclosed upfront payment.
